The most recent attempt by Merck & Co to help in shortening the Hepatitis C treatment to just four weeks by adding Gilead Sciences Inc’s high selling Sovaldi to their oral two-drug combination. According to the recent data from a mid-stage study, this attempt will help in decreasing the high rate of relapses, and help in reaching the desired efficiency.
There are several companies, which are also trying to find out ways to cure people from Hepatitis, and how to keep down the number of weeks of treatment for patients. This process is aimed at keeping the cure rates above 90 percent.
One of the just-approved pills known as Harvoni is combined with Sovaldi and another Gilead drug to help cure patients in eight weeks, and may take longer to treat serious patients.
The on-going Merck trial for untreated patients, there is only 38.7 percent patients with no detectable sign of the liver destroying virus, even after four weeks of the treatment of Hepatitis with Sovaldi. The selected data was set to be presented on Monday at the American Association for the Study of Liver Diseases (AASLD) meet-up at Boston.
The Hepatitis C field have been gaining pace at an alarming rate. Only a few years ago, there were patient that needed 48 weeks of treatments with drugs that had severe side effects and only cured around 40 percent of patients.
The new age of all-oral treatments are ready to eliminate the need of inject able interferon and flu-like side effects. In addition, other diseases like anaemia caused by drug called ribavirin will be cured with less treatment duration.
Latest posts by Anne-Marie Jackson (see all)
- A Trip And A Fall Led To The Discovery Of A 1 Million Years Old Fossil - Jul 21, 2017
- Giant Iceberg Breaks Free From Larsen C Ice Shelf - Jul 14, 2017
- EBLM J0555–57Ab Is The Smallest Star Ever Discovered Until Now - Jul 13, 2017